Long-term follow-up results of the multicenter phase II trial of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of standard tyrosine kinase inhibitor therapy
Ben-Ami, E., Barysauskas, C.M., von Mehren, M., Heinrich, M.C., Corless, C.L., Butrynski, J.E., Morgan, J.A., Wagner, A.J., Choy, E., Yap, J.T., Van den Abbeele, A.D., Solomon, S.M., Fletcher, J.A., Demetri, G.D., George, S.
Published in Annals of oncology (01.09.2016)
Published in Annals of oncology (01.09.2016)
Get full text
Journal Article